The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.
 
Takahiro Kogawa
No Relationships to Disclose
 
Emi Noguchi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Novartis; Pfizer
 
Takashi Yamanaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Kyowa Kirin; Lilly O.; Novartis; Pfizer
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical
 
Naohito Yamamoto
Research Funding - AstraZeneca (Inst); Pfizer (Inst)
 
Chi-Feng Chung
Consulting or Advisory Role - EirGenix
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Dwan-Ying Chang
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Eisai; Lilly O.; MSD; Novartis; Ono Pharmaceutical; Pfizer; Pierre Fabre; Roche; Sanofi; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Lilly O.; Novartis; Pfizer
Speakers' Bureau - Daiichi Sankyo Pharmaceutical
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagan (Inst)
 
Gun Min Kim
No Relationships to Disclose
 
Kyung-Hun Lee
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer
 
Soo-Chin Lee
Honoraria - ACT Genomics; AstraZeneca; Daiichi Sankyo Pharmaceutical; DKSH; Gilead Sciences; Lilly O.; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; MSD; Novartis; Pfizer; Roche
Research Funding - ACT Genomics; Eisai; Karyopharm Therapeutics; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Pfizer; Roche
 
Yoon Sim Yap
Honoraria - AstraZeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Specialised Therapeutics
Consulting or Advisory Role - AstraZeneca; Eisai; Inivata; Lilly; MSD; Novartis; Pfizer
Research Funding - MSD Oncology (Inst)
 
Yoshiko Umeyama
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Kazuki Sudo
Honoraria - AstraZeneca; Eisai; Nihon Medi-Physics; Pfizer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Merck; NanoCarrier; Pfizer; PRA Health Sciences; Takeda
 
Tomomi Hata
No Relationships to Disclose
 
Aya Kuchiba
Honoraria - Chugai Pharma
 
Taro Shibata
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; IQvia; Lilly; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kenji Tamura
No Relationships to Disclose
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)